SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
April
1, 2005
Date of
Report
(Date of
earliest event reported)
RITA
Medical Systems, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
000-30959 |
94-3199149 |
(Commission
File Number) |
(I.R.S.
Employer Identification No.) |
967
N. Shoreline Blvd.
Mountain
View, CA 94043
(Address
of principal executive offices, with zip code)
(650)
314-3400
(Registrant's
telephone number, including area code)
Item
8.01. Other
Events and Required FD Disclosure.
On April
1, 2005, RITA Medical Systems, Inc., a Delaware corporation (“RITA”),
announced publication of an article in the Journal of Clinical Oncology
documenting improved survival rates for colorectal liver metastases patients
treated with a combination of radiofrequency ablation and chemotherapy compared
to chemotherapy alone. A copy of RITA’s press release detailing the results of
the studies is attached as Exhibit 99.1 hereto and incorporated by reference
herein.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
RITA Medical
Systems, Inc. |
|
|
|
Date: April 1, 2005 |
By: |
/s/ Donald Stewart |
|
Donald
Stewart, Chief Financial Officer and
Vice
President Finance and Administration |
|
Title |
RITA
MEDICAL SYSTEMS, INC.
INDEX
TO EXHIBITS
Exhibit
Number |
Description |
|
|
|
|
99.1 |
Press
Release of RITA Medical Systems, Inc. dated April 1, 2005. |
|